Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.431NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.168NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
Q.6 (Alpha)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AZ.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.97NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.36.18NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.177.32NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.59NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.177.67NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.277NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.28 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.272NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.371NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AA.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.353NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-15625.1US
B.1.407NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AA.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.160.13NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.47NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.182NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.218NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.12.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
A.11NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.22 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BM.1.1.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBMNUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.34NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
CB.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BR.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.8NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
CL.1.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.2.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
CH.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
EF.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BR.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BE.8NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BH.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BL.1.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BS.1.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.13.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
DC.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.9NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
CP.1.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
EQ.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JU.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
CJ.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BM.1.1.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
DE.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.5.1.8NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used